Amábile-Cuevas Carlos F
Fundación Lusara, Mexico City, Mexico.
Infect Chemother. 2022 Sep;54(3):393-408. doi: 10.3947/ic.2022.0060. Epub 2022 Aug 5.
The antibiotic resistance arena is fraught with myths and misconceptions, leading to wrong strategies to combat it. It is crucial to identify them, discuss them in light of current evidence, and dispel those that are unequivocally wrong. This article proposes some concepts that may qualify as misconceptions around antibiotic resistance: the susceptible-resistant dichotomy; that incomplete antibiotic courses cause resistance; that resistance "emerges" in patients and hospitals; that antibiotics are mostly abused clinically; that resistance is higher in countries that use more antibiotics; that reducing antibiotic usage would reduce resistance; that financial incentives would "jumpstart" research and development of antibiotics; that generic and "original" antibiotics are the same; and that new anti-infective therapies are just around the corner. While some of these issues are still controversial, it is important to recognize their controversial status, instead of repeating them in specialized literature and lectures and, especially, in the planning of strategies to cope with resistance.
抗生素耐药领域充斥着神话和误解，导致对抗生素耐药的应对策略出现偏差。识别这些问题、根据现有证据进行讨论并消除那些明显错误的观念至关重要。本文提出了一些可能被视为关于抗生素耐药的误解的观点：敏感与耐药二分法；抗生素疗程不完整会导致耐药；耐药在患者和医院中“出现”；抗生素在临床上大多被滥用；使用更多抗生素的国家耐药性更高；减少抗生素使用会降低耐药性；经济激励会“启动”抗生素的研发；仿制药和“原研”抗生素相同；以及新的抗感染疗法即将问世。虽然其中一些问题仍存在争议，但重要的是要认识到它们的争议性，而不是在专业文献、讲座中，尤其是在应对耐药性的策略规划中重复这些观点。
